Marc R. Larochelle

Marc R. Larochelle

Auto-generated profile, based on publicly available information

Marc R. Larochelle

Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MLMarc R. Larochelle
Marc R. Larochelle
DBDana Bernson
Dana Bernson
TLThomas Land
Thomas Land
TSThomas J. Stopka
Thomas J. Stopka
NWNa Wang
Na Wang
AWAlexander Y. Walley
Alexander Y. Walley
Patients who survive an opioid overdose are at increased risk for subsequent nonfatal and fatal events. This study evaluated overdose survivors to determine whether use of medications for opioid us... Background: Opioid overdose survivors have an increased risk for death. Whether use of medications for opioid use disorder (MOUD) after overdose is associated with mortality is not known. Objective...

1 November 2019 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MLMarc R. Larochelle
Marc R. Larochelle
RBRyan Bernstein
Ryan Bernstein
DBDana Bernson
Dana Bernson
TLThomas Land
Thomas Land
TSThomas J Stopka
Thomas J Stopka
AWAlexander Y. Walley
Alexander Y. Walley

1 October 2021 in American Journal of Public Health
Verified
Journal Article
Closed access
MLMarc R. Larochelle
Marc R. Larochelle
SSSvetla Slavova
Svetla Slavova
ERElisabeth D. Root
Elisabeth D. Root
DFDaniel J. Feaster
Daniel J. Feaster
PWPatrick J. Ward
Patrick J. Ward
JSJeffrey H. Samet
Jeffrey H. Samet
Objectives. To examine trends in opioid overdose deaths by race/ethnicity from 2018 to 2019 across 67 HEALing Communities Study (HCS) communities in Kentucky, New York, Massachusetts, and Ohio. Methods. We used state death certificate records to calculate opioid overdose death rates per 100 000 adult residents of the 67 HCS communities for 2018 and 2019. We used Poisson regression to calculate the ratio of 2019 to 2018 rates. We compared changes by race/ethnicity by calculating a ratio of rate ratios (RRR) for each racial/ethnic group compared with non-Hispanic White individuals. Results. Opioid overdose death rates were 38.3 and 39.5 per 100 000 for 2018 and 2019, respectively, without a significant change from 2018 to 2019 (rate ratio = 1.03; 95% confidence interval [CI] = 0.98, 1.08). We estimated a 40% increase in opioid overdose death rate for non-Hispanic Black individuals (RRR = 1.40; 95% CI = 1.22, 1.62) relative to non-Hispanic White individuals but no change among other race/ethnicities. Conclusions. Overall opioid overdose death rates have leveled off but have increased among non-Hispanic Black individuals. Public Health Implications. An antiracist public health approach is needed to address the crisis of opioid-related harms. (Am J Public Health. 2021;111(10):1851–1854. https://doi.org/10.2105/AJPH.2021.306431 )

5 January 2016 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MLMarc R. Larochelle
Marc R. Larochelle
JLJane M. Liebschutz
Jane M. Liebschutz
FZFang Zhang
Fang Zhang
DRDennis Ross-Degnan
Dennis Ross-Degnan
JWJ. Frank Wharam
J. Frank Wharam
Nonfatal opioid overdose is an opportunity to identify and treat substance use disorders, but treatment patterns after the overdose are unknown. To determine prescribed opioid dosage after an opioid overdose and its association with repeated overdose. Retrospective cohort study. A large U.S. health insurer. 2848 commercially insured patients aged 18 to 64 years who had a nonfatal opioid overdose during long-term opioid therapy for noncancer pain between May 2000 and December 2012. Nonfatal opioid overdose was identified using International Classification of Diseases, Ninth Revision, Clinical Modification, codes from emergency department or inpatient claims. The primary outcome was daily morphine-equivalent dosage (MED) of opioids dispensed from 60 days before to up to 730 days after the index overdose. We categorized dosages as large (≥100 mg MED), moderate (50 to <100 mg MED), low (<50 mg MED), or none (0 mg MED). Secondary outcomes included time to repeated overdose stratified by daily dosage as a time-varying covariate. Over a median follow-up of 299 days, opioids were dispensed to 91% of patients after an overdose. Seven percent of patients (n = 212) had a repeated opioid overdose. At 2 years, the cumulative incidence of repeated overdose was 17% (95% CI, 14% to 20%) for patients receiving high dosages of opioids after the index overdose, 15% (CI, 10% to 21%) for those receiving moderate dosages, 9% (CI, 6% to 14%) for those receiving low dosages, and 8% (CI, 6% to 11%) for those receiving no opioids. The cohort was limited to commercially insured adults. Almost all patients continue to receive prescription opioids after an overdose. Opioid discontinuation after overdose is associated with lower risk for repeated overdose. Health Resources and Services Administration.

1 June 2018 in Health Affairs
Verified
Journal Article
Closed access
RHRebecca L. Haffajee
Rebecca L. Haffajee
MMMichelle M. Mello
Michelle M. Mello
FZFang Zhang
Fang Zhang
AZAlan M. Zaslavsky
Alan M. Zaslavsky
MLMarc R. Larochelle
Marc R. Larochelle
JWJ. Frank Wharam
J. Frank Wharam
State prescription drug monitoring programs (PDMPs) aim to reduce risky controlled-substance prescribing, but early programs had limited impact. Several states implemented robust features in 2012–13, such as mandates that prescribers register with the program and regularly check its registry database. Some states allow prescribers to fulfill the latter requirement by designating delegates to check the registry. The effects of robust PDMP features have not been fully assessed. We used commercial claims data to examine the effects of implementing robust PDMPs in four states on overall and high-risk opioid prescribing, comparing those results to trends in similar states without robust PDMPs. By the end of 2014 the absolute mean morphine-equivalent dosages that providers dispensed declined in a range of 6–77 mg per person per quarter in the four states, relative to comparison states. Only in one of the four states, Kentucky, did the percentage of people who filled opioid prescriptions decline versus its compa...

22 April 2015 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
MLMarc R. Larochelle
Marc R. Larochelle
FZFang Zhang
Fang Zhang
DRDennis Ross-Degnan
Dennis Ross-Degnan
JWJ. Frank Wharam
J. Frank Wharam